Addis, A. & Koren, G. (2000) Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychological Medicine, 30, 89–94.
Altshuler, L. L., Cohen, L., Szuba, M. P.
et al (1996) Pharmacological management of psychiatric illness during pregnancy: dilemmas and guidelines. American Journal of Psychiatry, 153, 592–606.
Amminger, G. P., Pope, S., Rock, D.
et al (1999) Relationship between childhood behavioural disturbance and later schizophrenia in the New York High Risk Project. American Journal of Psychiatry, 156, 525–530.
Ananth, J. (1975) Congenital malformations with psychopharmacological agents. Comprehensive Psychiatry, 16, 437–445.
Baldessarini, R. J., Tondo, L., Faedda, G. L.
et al (1996) Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorders. Journal of Clinical Psychiatry, 57, 441–448.
Bennedsen, B. E. (1998) Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophrenia Research, 33, 1–26.
Bergman, A. J., Wolfson, M. A. & Walker, E. F. (1997) Neuromotor functioning and behaviour problems in children at risk for psychopathology. Journal of Abnormal Child Psychology, 25, 229–237.
Briggs, G. G., Freeman, R. K. & Yaffee, S. J. (1994) A Reference Guide to Foetal and Neonatal Risk: Drugs in Pregnancy and Lactation. Baltimore, MD: Williams & Wilkins.
Butters, L. & Howie, C. (1990) Awareness among pregnant women of the effect on the foetus of commonly used drugs. Midwifery, 6, 146–154.
Clayton-Smith, J. & Donnai, D. (1995) Foetal valproate syndrome. Journal of Medical Genetics, 32, 724–727.
Cohen, L. S., Friedman, J. M., Jefferson, J. W.
et al (1994) A re-evaluation of risk of in utero exposure to lithium. JAMA, 271, 146–150.
Crombie, D. L., Pincent, R. J. & Fleming, D. (1972) Imipramine and pregnancy (letter). BMJ, 2, 745.
Desmond, M. M., Rudolph, A. J., Hill, R. M.
et al (1969) Behavioural alterations in infants born to mothers on psychoactive medication during pregnancy. In Congenital Mental Retardation (ed. Farrell, G.) pp. 235–244. Austin, TX: University of Texas Press.
Einarsen, A., Bumn, F., Sarkar, M.
et al (2001) Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. American Journal of Psychiatry, 158, 1728–1730.
Ericson, A., Kallen, B. & Wiholm, B. (1999) Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology, 55, 503–508.
Goldstein, D. J. (1995) Effects of third trimester fluoxetine exposure on the newborn. Journal of Clinical Psychopharmacology, 15, 417–420.
Hamilton, J. A. & Yonkers, K. A. (1996) Sex differences in pharmacokinetics of psychotropic medication. In Psychopharmacology and Women: Sex, Gender, Hormones (eds Jensvold, M. F., Halbreich, U. & Hamilton, J. A.) pp. 11–42. Washington, DC: American Psychiatric Press.
Hauser, L. A. (1985) Pregnancy and psychotropic drugs. Hospital and Community Psychiatry, 36, 817–818.
Heath, C. & Yonkers, K. A. (2001) Somatic treatments in depression: concerns during pregnancy and breastfeeding. In Management of Psychiatric Disorders in Pregnancy (eds Yonkers, K. A. & Little, B. B.) pp. 82–104. Oxford: Arnold.
Kallen, B. & Tandberg, A. (1983) Lithium and pregnancy: a cohort study on manic depressive women. Acta Psychiatrica Scandinavica, 68, 134–139.
Kendell, R. E., Chalmers, J. C. & Platz, C. (1987) Epidemiology of puerperal psychosis. British Journal of Psychiatry, 150, 662–673.
Koch, S., Jager-Roman, E., Losche, G.
et al (1996) Anti-epileptic drug treatment in pregnancy: drug side-effects in neonates and neurological outcome. Acta Paediatrica, 85, 739–746.
Kopelman, A. E., McCullar, F. W. & Heggeness, L. (1975) Limp malformations following maternal use of haloperidol. JAMA, 231, 62–64.
Koren, G., Pastuszak, A. & Ito, S. (1998) Drugs in pregnancy. New England Journal of Medicine, 338, 1128–1137.
Kulin, N. A., Pastuszak, A., Sage, S. R.
et al (1998) Pregnancy outcome following maternal use of selective serotonin reuptake inhibitors. JAMA, 279, 609–610.
Little, B. B. (1999) Pharmakokinetics during pregnancy: evidence based maternal dose formulation. Obstetrics and Gynaecology, 93, 858–868.
McElhatton, P. R., Garbis, H. M., Elefant, E.
et al (1996) The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Service (ENTIS). Reproductive Toxicology, 10, 285–294.
McElhatton, P. R., Bateman, D. N., Evans, C.
et al (1998) Does prenatal exposure to ecstasy cause congenital malformation? A prospective follow-up of 92 pregnancies. British Journal of Clinical Pharmacology, 45, 184.
McElhatton, P. R., Bateman, D. N., Evans, C.
et al (1999) Congenital anomalies after prenatal ecstasy exposure. Lancet, 354, 1441–1442.
Miller, L. J. (1991) Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatric Medicine, 9, 275–298.
Murray, L. & Cooper, P. J. (1997) Postpartum Depression and Child Development. New York: Guilford Press.
Nordeng, H., Lindemann, R., Perminov, K. V.
et al (2001) Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatrica, 90, 288–291.
Nulman, I., Rovet, J., Stewart, D. E.
et al (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. New England Journal of Medicine, 336, 258–262.
Nulman, I., Rovet, J., Stewart, D. E.
et al (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout foetal life: a prospective controlled study. American Journal of Psychiatry, 159, 1889–1895.
Oates, M. (2001) Death from psychiatric causes. In Why Mothers Die 1997–1999: Confidential Enquiries into Maternal Deaths in the United Kingdom (eds Lewis, G. & Drife, J.) pp. 165–187. London: Royal College of Obstetricians and Gynaecologists Press.
Orr, S. T. & Miller, C. A. (1995) Maternal depressive symptoms and risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiology Review, 17, 165–171.
Pastuszak, A., Schick-Boscheta, B., Zuber, C.
et al (1993) Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA, 269, 2246–2248.
Rubin, P. C. (1981) Current concepts: beta blockers in pregnancy. New England Journal of Medicine, 305, 1323–1326.
Rubin, P. C. (ed.) (1995) Prescribing in Pregnancy (2nd edn). London: BMJ Publishing.
Rubin, P. C. (1998) Drug treatment during pregnancy. BMJ, 317, 1503–1506.
Rutter, M. (1997) Maternal depression and infant development: cause and consequence, sensitivity and specificity. In Postpartum Depression and Child Development (eds Murray, L. & Cooper, P. J.) pp. 295–315. New York: Guilford Press.
Sacker, A., Done, D. J. & Crow, T. J. (1996) Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case control studies. Psychological Medicine, 26, 279–287.
Scolnik, D., Nulman, I., Rovet, J.
et al (1994) Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA, 271, 767–770.
Sickel, D. A., Cohen, L. S., Dimmach, J. A.
et al (1993) Postpartum obsessive compulsive disorders: a case series. Journal of Clinical Psychiatry, 54, 156–159.
Simon, G. E., Cunningham, M. L. & Davis, R. L. (2002) Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry, 159, 2055–2061.
Slone, D., Siskind, V., Heinonen, R. P.
et al (1977) Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight and intelligence quotient score. American Journal of Obstetrics and Gynecology, 128, 486–488.
Stowe, Z. N. & Nemeroff, C. B. (1998) Psychopharmacology during pregnancy and lactation. In Textbook of Psychopharmacology (eds Schatzberg, A. F. & Nemeroff, C. B.) pp. 823–837. Washington, DC: American Psychiatric Press.
Tekell, J. L. (2001) Managing pregnancy in the schizophrenic woman. In Management of Psychiatric Disorders in Pregnancy (eds Yonkers, K. A. & Little, B. B.) pp. 188–212. Oxford: Arnold.
Van Waes, A. & van de Velde, E. (1969) Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. Journal of Clinical Psychopharmacology, 9, 224–237.
Viguera, A. C. & Cohen, L. S. (2002) Pharmacological management of psychiatric illness during pregnancy: weighing the risks In Psychiatric Illness in Women (eds Lewis Hall, F., Williams, T. S., Panetta, J. A.
et al), pp. 577–606. Washington, DC: American Psychiatric Publishing.
Viguera, A. C., Nonacs, R., Cohen, L. S.
et al (2000) Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. American Journal of Psychiatry, 157, 179–184.
Wisner, K. L. & Perel, J. M. (1988) Psychopharmacological agents and electroconvulsive therapy during pregnancy and the puerperium. In Psychiatric Consultation in Childbirth Settings (ed. Cohen, P. L.) pp. 165–206. New York: Plenum.
Wisner, K. L. & Perel, J. M. (1996) Psychopharmacological treatment during pregnancy and lactation. In Psychopharmacology and Women: Sex, Gender and Hormones (eds Jensvold, M. F., Halbreich, U. & Hamilton, J. A.) pp. 191–224. Washington, DC: American Psychiatric Press.
Wisner, K. L., Gelenberg, A. J., Leonard, H.
et al (1999) Pharmacological treatment of depression during pregnancy. JAMA, 282, 1264–1269.
Zuckerman, B., Bauchner, H., Parker, S.
et al (1990) Maternal depressive symptoms during pregnancy and newborn irritability. Developmental and Behavioural Paediatrics, 11, 190–194.